Lagosa (Silymarin)

Silymarin works by providing antioxidant protection, scavenging free radicals, and inhibiting lipid peroxidation in liver cells. It stabilises cell membranes, promotes protein synthesis in hepatocytes, and modulates inflammatory pathways, which together help preserve liver integrity and support regeneration.

The appropriate dose of Lagosa is determined by a qualified prescriber based on the individual’s health status, age, and therapeutic goals. Because formulations can vary, patients should follow the specific dosing instructions provided by their healthcare professional.

Safety data for silymarin during pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss the use of Lagosa with their healthcare provider to weigh potential benefits against unknown risks.

To order Lagosa, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lagosa’s active ingredient, silymarin, is a well‑studied component of milk thistle extracts and is comparable to other herbal hepatoprotective agents. Unlike synthetic liver drugs, it offers a natural antioxidant profile, but clinical potency may differ from prescription‑only options, making it suitable for mild to moderate liver support under professional guidance.

Lagosa should be stored at ambient temperature, ideally below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Lagosa is taken orally, typically in tablet or capsule form, as directed by a healthcare professional. It is swallowed with water and can be taken with or without food, depending on the prescriber’s recommendation.

The most serious risks include rare but severe allergic reactions such as anaphylaxis, unexpected elevation of liver enzymes indicating possible liver stress, and jaundice. Patients experiencing any of these symptoms should seek immediate medical attention.

Individuals with known hypersensitivity to silymarin or any component of the formulation should avoid Lagosa. It is also contraindicated for patients with severe liver disease who have not been evaluated by a physician, and for those taking medications that may interact significantly without proper monitoring.